[fam-] trastuzumab deruxtecan (DS-8201) - Daiichi Sankyo
DS-8201: Data from P3 DESTINY-Breast03 trial (NCT03529110) for HER2-positive, unresectable and/or metastatic breast cancer in 2020 or later (AstraZeneca) - Apr 26, 2019 - Q1 2019 Results: Data from P3 DESTINY-Breast04 trial (NCT03734029) for HER2-low, unresectable and/or metastatic breast cancer in 2020 or later 
P3 data
https://www.astrazeneca.com/investor-relations/results-and-presentations.html
 
Apr 26, 2019
 
 
a40ca2f7-47a0-4818-93bd-1cf6342fe3ad.jpg